This site is intended for U.S. healthcare professionals.
Menu
Close
Efficacy
Phase III Study Primary Endpoints
Success in ISGA: Clear or almost clear
Study Design
Phase III Study Secondary Endpoints
ISGA clear or almost clear
Time to ISGA success
Phase III Study: Other Endpoints
Pruritus
Quality of life assessments
Infant Study: Exploratory efficacy Endpoints
ISGA clear or almost clear
%BSA, EASI & POEM
Safety Data
Phase III Study Adverse Reactions*
Pivotal trial & 48-week extension study
Adverse Reactions
Open-Label Safety Extension Study*
Open-Label Safety Extension Study Rescue Therapy Endpoint
Study design
Infant Safety Study**
Adverse Reactions
Study design and Demographics
Savings & Support
Events
Materials
Videos
Copay Cards
Cost and Coverage
Pooled data from the pivotal trials of patients aged 2 and up: an exploratory post hoc analysis with 28 days of treatment11
POOLED
INDIVIDUAL
*Baseline was the mean of at least 2 SPS assessments on Day 1. SPS daily values were the mean of at least 2 SPS assessments on that day9.
†Proportion of patients and their reported SPS scores at Baseline: Mild: EUCRISA 24% (n=183) and Emollient-rich Vehicle 28% (n=104). Severe: EUCRISA 28% (n=214) and Emollient-rich Vehicle 26% (n=98).
Pivotal Trial
Post Hoc
The SPS is a patient- or parent/guardian-reported outcome using a 4-point scale measuring pruritus over the past 24 hours.
None: No itching
Mild: Occasional, slight itching/scratching
Moderate: Constant or intermittent itching/scratching which is not disturbing sleep
Severe: Bothersome itching/scratching which is disturbing sleep
Please note: Sleep disturbance was not measured in this assessment and was only used as a descriptive anchor in the verbal rating scale to indicate higher levels of itch severity.
Pooled data results from an exploratory post hoc analysis*
POOLED
TRIAL 1
TRIAL 2
*Baseline was the mean of at least 2 SPS assessments on Day 1. SPS daily values were the mean of at least 2 SPS assessments on that day.
†Improvement was defined as a weekly mean SPS score of ≤1 with at least a 1-point improvement from baseline.9
Comparisons between EUCRISA and Emollient-rich Vehicle cannot be made as the study was not designed for this purpose.9
This study reflects information from the pivotal trial where patients enrolled were 2 years and older.
Find out more about the proportion of patients who achieved clear or almost clear at day 29 in the primary endpoint
** This is an optional area where footnotes can live.
Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him
Not an actual patient
Learn more about 28-day, open-label, single-arm, safety study in 3 to <24 month old patients14
** This is an optional area where footnotes can live.
Find out more about the proportion of patients aged 2 years and older who achieved ISGA clear or almost clear at day 29 from the Phase III trial's secondary endpoint
** This is an optional area where footnotes can live.
The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4
** This is an optional area where footnotes can live.
*Eligible patients pay as little as $10
Terms and Conditions apply
* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.
** This is an optional area where footnotes can live.
A savings and support program for your patients to help them with their access to EUCRISA
** This is an optional area where footnotes can live.
Register or sign in to check availability and request samples.
** This is an optional area where footnotes can live.
Contraindications
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
Adverse Reactions
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
Please see Full Prescribing Information and Patient Information
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?